Dianthus Therapeutics, Inc. · NASDAQ:DNTH

Vestal Point Capital, LP reported a 9.95% stake in Dianthus Therapeutics, Inc. (Schedule 13G/A)

Event Jun 30, 2025 · Filed Aug 14, 2025

Vestal Point Capital, LP reported a 9.95% stake in Dianthus Therapeutics, Inc., 3,200,000 shares, as a passive investor on Jun 30, 2025. Filed Aug 14, 2025 (Schedule 13G/A).

Stake
9.95%
Shares
3,200,000
Intent
Passive
What changed
Stake changed
Filed together
2 holders

The filing in full

HolderStakeShares
Vestal Point Capital, LP9.95%3,200,000
Ryan Wilder9.95%3,200,000

Source

View original at SEC

Related